What is PRINTO?

Short History of PRINTO

The Paediatric Rheumatology INternational Trials Organisation (PRINTO at www.printo.it) is a non-profit, non-governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. PRINTO, which initially included 14 European countries, represents currently a network of more than 700 centres with 2000 members from 94 countries worldwide. The goal of our organization is to foster, facilitate and coordinate the development, conduct, analysis, and reporting of multicentre, international clinical trials and outcome standardisation studies in children with paediatric rheumatic diseases (PRD).

PRINTO also fosters the training of young fellows in Paediatric Rheumatology through different education fellowship programs.

PRINTO Coordinating Centre

The International Coordinating Centre is based in Genoa at IRCCS Istituto Giannina Gaslini, one of the biggest children’s hospitals in Italy. The chief function of the International Coordinating Centre is to facilitate the flow of the logistic and scientific aspects necessary to design, launch and manage multicentre, multi-national, collaborative studies.

The PRINTO Academic Research Activities

PRINTO acts as an international academic research service to the paediatric rheumatology community for the implementation of non-profit trials and other studies initiated by investigators (consensus projects, cross-cultural adaptation of questionnaires, training, standardized information for families, etc.).

Many projects coordinated by the network have been funded by the European Union or other public entities. Currently, PRINTO is coordinating the following projects:

- The JIA classification study: the PRINTO Evidence-Based revision of the International League Against Rheumatism (ILAR) Classification criteria for juvenile idiopathic Arthritis;
- The STARS trial: interventional clinical trial for the comparison of Step-up and step-down therapeutic strategies in childhood Arthritis;
- Pharmachild: pharmacovigilance JIA registry;
- Eurofever: registry of patients (children and adults) with autoinflammatory diseases;
- The DAISY Study: with the support of FOREUM, (Foundation for Research in Rheumatology), this study aims to define the applicability of standardized ultrasound examination to estimate disease activity in combination with JADAS and inflammation markers in JIA patients;
- The International registry on COVID-19 related Hyperinflammation in children and young adults, HyperPED-COVID, is a multicentre effort to collect information on clinical presentation, laboratory parameters, clinical outcome and response to treatment of patients with COVID-19 related hyperinflammation.
- The CEST-JIA study is an interventional trial aiming to compare the safety and efficacy of adalimumab and etanercept originator molecules vs biosimilars in the treatment of polyarticular course JIA as well as to evaluate safety and efficacy of switching from originator biological molecules to bsDMARDS and vice-versa.

As a result of academic initiatives, more than 43,000 patients have been enrolled from about 360 centres in 67 different countries.

Collaboration with Pharmaceutical Companies

PRINTO collaborates with several pharmaceutical companies in the paediatric investigation plan (PIP), protocol and case report form development, site selection through dedicated feasibilities among PRINTO members, training, monitoring, analysis and reporting of clinical trials.

As a result of this collaboration, over 3,900 patients have been enrolled from more than 270 centres in 44 different countries.

Publications: More than 270 scientific papers have been published, including 917 authors from 64 countries, with 51% of them in multiple publications.

https://www.printo.it/publications/papers

PRINTO for Families: PRINTO has created a dedicated website which offers scientific information regarding the paediatric rheumatic diseases (PRD), the list of centres dealing with PRD, and the list of the family associations in more than 60 languages. The information reported in the website allows families to have a clear picture of the current standards of care of patients affected by pediatric rheumatic diseases.

www.printo.it/pediatric-rheumatology
Why being a PRINTO member

As a PRINTO member you will be actively involved in the projects developed and coordinated by the network which will result in international publications.

In 2023, PRINTO has reached more than 2000 members in 717 international centres from 94 countries worldwide.

If you wish to become a PRINTO member and to receive regular updates about our research activity and invitations to our projects, please follow the link below:

www.printo.it/contact/apply-membership

Your cooperation will be more than welcome and your effort will contribute to the research of paediatric rheumatic diseases.

PRINTO member countries in the world

---

PRINTO coordinating centre - Contacts

Paediatric Rheumatology INternational Trials Organisation
c/o IRCCS Istituto Giannina Gaslini
UOC Gaslini Trial Centre / SSCP
EULAR Centre of Excellence in Rheumatology
Via Gerolamo Gaslini 5, 16147 Genoa, Italy
Tel.: +39-010-384254 or +39-010-393425
Fax: +39-010-4211018 or +39-010-393324
Email: printo@gaslini.org
Website: http://www.printo.it/pediatric-rheumatology/
https://www.printo.it/pediatric-rheumatology/

---

Chairman
Alberto Martini, MD, Prof - Genoa

Senior Scientist
Nicolino Ruoppo, MD, MPH - Genoa

Counsellors
Tadej Avcin, MD, PhD - Ljubljana
Michael Hofer, MD, Prof - Lausanne
Sefa Ozan, MD, Prof - Ankara
Pierre Quartier, MD - Paris
Claudia Saad Magalhães, MD, Prof - Botucatu
Joost Swart, MD, PhD - Utrecht